AIMP2 Antibody
| Code | Size | Price |
|---|
| PSI-7515-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7515-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
AIMP2 Antibody: P38, JTV1, JTV-1, PRO0992, Aminoacyl tRNA synthase complex-interacting multifunctional protein 2, Multisynthase complex auxiliary component p38
Application Note:
AIMP2 antibody can be used for detection of AIMP2 by Western blot at 1 - 2 μg/ml.
Antibody validated: Western Blot in human samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
AIMP2 was initially identified as a part of an aminoacyl-tRNA synthesase complex (1). It was later discovered to be a cofactor and substrate of Parkin, a Ring-type E3 ubiquitin ligase that is important for the survival of dopamine neurons in Parkinson?s disease; accumulation of AIMP2 in these cells lead to catecholaminergic cell death (2). AIMP2 can also bind to TRAF2, a key player in the TNF-alpha signaling pathway, causing the ubiquitination of TRAF2 by cIAP1, leading to TNF-alpha-dependent apoptosis (3). Finally, AIMP2 has been suggested to function as a tumor suppressor (4).
Background References:
- Quevillon S, Robinson JC, Berthonneau E, et al. Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein. J. Mol. Biol. 1999; 285:183-95.
- Ko HS, von Coelln R, Sriram SR, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neruosci. 2005; 25:7968-78.
- Choi JW, Kim DG, Park MC, et al. AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2. J. Cell Sci. 2009; 122:2710-5.
- Choi JW, UM JY, Kundu JK, et al. Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. Carcinogenesis 2009; 30:1638-44.
Buffer:
AIMP2 antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
AIMP2 antibody was raised against a 16 amino acid peptide near the center of human AIMP2.
The immunogen is located within amino acids 150 - 200 of AIMP2.
The immunogen is located within amino acids 150 - 200 of AIMP2.
NCBI Gene ID #:
7965
NCBI Official Name:
aminoacyl tRNA synthetase complex-interacting multifunctional protein 2
NCBI Official Symbol:
AIMP2
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 35 kDa
Observed: 36 kDa
Observed: 36 kDa
Protein Accession #:
NP_006294
Protein GI Number:
11125770
Purification:
AIMP2 antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis
SPECIFICITY:
AIMP2 antibody is human specific. AIMP2 antibody is predicted to not cross-react with AIMP1.
Swissprot #:
Q13155
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | AIMP2 Peptide | PSI-7515P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|